Trial abstract · §3
SELANK-RU-ANXIETY — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Anxiety symptom scores | As for semax. The Institute records the absence of a retrievable controlled trial | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Selank from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nasal irritation | — | — | Reported |
| No sedation reported | — | — | A consistent claim across the available reports |
| No withdrawal syndrome reported | — | — | Reported; ascertainment methodology not described |
Compound Evidence Institute · CEI-TR-0126/3 · https://compoundevidence.com/trials/selank-ru-anxiety/results/ · retrieved 30 July 2026